Sector intelligence and perspective

Solid Biosciences (SLDB) clinical hold removed on SGT-001 DMD (Duchenne muscular dystrophy) treatment

June 18, 2018

SLDB closed up +$1.81 on Friday and is up +$2.70 or +10.19% in the pre-market   The clinical hold was imposed in March and came after the unexpected hospitalization of a patient in the P1/2 trial, called Ignite DMD.

MiMedx Group (MDXG) crashes after news of a 5 year restatement and CFO departs

June 7, 2018

MDXG is a moving downside of -$1.29 or approximately -15.35% to $6.92 After a previous close of $8.32 and an opening bid of $5.88   Interesting “stat”:  In 2017, the average restatement covered 509 days, the lowest value since 2009, according to Audit Analytics. MDXG’s restatement will cover nearly 2,099 days or roughly four times the average <WSJ>.

Roll Call

The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.